Carlsmed, Inc. (Nasdaq: CARL) announced preliminary and unaudited revenue for Q4 and FY 2025.
Q4 2025 revenue: ~$15.2 million, 61% growth over Q4 2024.
FY 2025 revenue: ~$50.5 million, 86% growth over 2024.
Transformational Year
Commercial performance capped a transformative year for Carlsmed with the power of aprevo®.
Surgeon User Growth
Added 101 new surgeon users in 2025, a 61% increase over the prior year.
Strategy Focus
Focused on executing growth strategy with operational excellence in 2026.
Product Launch
Recent launch of aprevo® cervical with positive early surgeon feedback.
- Carlsmed's AI-enabled personalized spine surgery solutions show promising growth.
- Expectation for growing recognition and adoption of aprevo® as a transformative platform technology.
Carlsmed anticipates updating the unaudited revenue results and continues towards transformative growth in spine surgery solutions.